Our cash inflows and the amounts of expenditures that will be necessary to execute our business plan are subject to numerous uncertainties , including but not limited to : changes in drug-eluting coronary stent markets , including the impact of new competitive entrants into such markets , and the sales achieved in such markets by our partner BSC , the timing and success of product sales and marketing initiatives and new product launches , the timing and success of our research , product development and clinical trial activities , the timing of completing certain operational initiatives , our ability to effect reductions in certain aspects of our budgets in an efficient and timely manner , and changes in interest rates .